
Median Technologies Signs Financial Agreement for up to €37.5 Million New Financing Facility With the European Investment Bank (EIB)
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, 'Median' or the 'Company'), manufacturer of eyonis ®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company signed a financial agreement with the European Investment Bank (EIB) for a new financing facility of up to €37.5 million, on July 11, 2025.
The signature of the financial agreement is in line with previous announcements on January 24, 2025, and April 24, 2025 stating that Median and the EIB were working to conclude an agreement for a new financing facility.
'We welcome the conclusion of our discussions with the European Investment Bank and the signature of the financial agreement', said Fredrik Brag, CEO and Founder of Median Technologies. 'We are very honored to belong to the European innovative ecosystem supported by the EIB, and to contribute to the European technological sovereignty. Proceeds from this new EIB financing facility will strengthen our financial independence to negotiate the best possible options for the commercialization of eyonis ® LCS in U.S. and in Europe.'
Financing Facility Structure
The EIB 2025 financing facility could be drawn in three (3) tranches, i.e., €19 million (Tranche A), €8.5 million (Tranche B) and €10 million (Tranche C).
Median Technologies will request the drawdown of the €19 million Tranche A, as soon as all contractual conditions with respect to such tranche, are satisfied, specifically:
Full issuance of the EIB new Tranche A warrants to the EIB and registration, in accordance with the warrant issuance agreement,
Completion of a share capital increase for an amount at least equal to €16 million (issuance premium included),
Repayment of the first tranche of the previous EIB 2019 loan, for which the maturity has been extended from April to October 2025.
Furthermore, the Company has undertaken to have secured by June 30, 2026, incremental equity financing in a total amount of at least €10 million.
The characteristics of tranche A are:
Maturity of 72 months, and monthly amortization over a period of 36 months after a 36-month grace period,
Annual interest rate of 5%.
The release of the tranche A of €19 million will result in the issuance of warrants which quantity and exercise price will depend on the stock price on the date of issuance. At current trading stock price, and after fulfilment of all drawdown conditions, the total amount of shares resulting from the exercise of the warrants would represent 10% of the share capital.
As stated in the financial agreement, Tranche B and Tranche C disbursements remain at Median's discretion, subject to certain conditions which are specified in the financial agreement.
Intended use of proceeds
The EIB funds will be to support eyonis ® Lung Cancer Screening (LCS) progress towards major milestones consisting of commercial launch and sales development in the U.S and in Europe, and to accelerate the expansion of Median's proprietary suite of Software as a Medical Device, eyonis ®, for image-based early cancer diagnosis, notably the scientific and clinical development of eyonis ® IPN for incidental findings of pulmonary nodules, and eyonis ® HCC, for primary liver cancer early diagnosis.
eyonis ® LCS progress status and next steps
Regulatory filings for marketing in U.S. and Europe and marketing authorizations:
On May 14, 2025, Median Technologies announced the filing of an application to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of eyonis ® LCS.
On July 1, 2025, the Company announced the filing of an application for Class IIb CE marking of eyonis ® LCS.
Given the usual timelines for regulatory review, the U.S. FDA 510(k) clearance for eyonis ® LCS is expected around the end of Q3 2025, expected to be followed by commercial launch in the US. Median Technologies expects European marketing authorization for eyonis ® LCS as soon as Q1 2026.
Commercial launch
Median Technologies is actively engaged in discussions with several leading players in AI- diagnostic and imaging equipment manufacturing, for the commercialization of eyonis ® LCS. Some of these strategic partnerships are expected to be finalized upon FDA marketing authorization of eyonis ® LCS.
The Company has finalized its US market access strategy, based on a comprehensive mapping of medical institutions involved in screening procedures, particularly in the United States, eyonis ® LCS' first and leading market. This mapping has enabled the identification of health institutions generating the highest volume of lung cancer screening procedures, positioning them as key drivers for the commercial launch of eyonis ® LCS.
Discussions with U.S. payers will be initiated upon FDA marketing authorization. At this stage, preliminary studies have been conducted to estimate the projected economic benefits of using eyonis ® LCS in lung cancer screening programs. To date, the Company has developed a detailed mapping of payers in the United States. Furthermore, an initial analysis based on a health economics Markov model simulating lung cancer progression over five years and incorporating the performance of eyonis ® LCS, demonstrates that eyonis ® LCS enhances early detection and characterization, reduces unnecessary health procedures, and generates significant cost savings for U.S. payers. The results of this preliminary analysis were presented at ISPOR 2025, the leading global conference for health economics and market access, held this past May. Results from the study are available on Median's website.
Over the past year, the Median eyonis ® team has built a very substantial network of early adopters composed of key opinion leaders. The team has conducted numerous visits to leading healthcare institutions and actively participated in major medical conferences organized by medical societies in pulmonology, oncology, and radiology, both in the U.S. and Europe, including the Radiological Society of North America (RSNA), the European Radiology Society (ESR), the American Thoracic Society (ATS), the European Society of Thoracic Imaging (ESTI), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO). The Company now enjoys strong recognition of its eyonis ® LCS technology within the medical community, along with a strong brand image associated with the product. Most of the leading healthcare institutions in contact with Median have expressed interest in participating in future health economics studies, which will be launched following regulatory market approvals.
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates, as well as the assumptions on which these are based, statements concerning projects, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, or future performance.
These forward-looking statements can often be identified by the words "expects," "anticipates," "believes," "intends," "estimates" or "plans" and any other similar expressions. Although Median's management believes that these forward-looking statements are reasonable, investors are cautioned that forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median Technologies, that could cause actual results and events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
All forward-looking statements in this press release are based on information available to Median Technologies as of the date of the press release. Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Autorité des Marchés Financiers.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Travel Weekly
28 minutes ago
- Travel Weekly
European acquisition revives Space Perspective's space tourism ambitions
Space Perspective has been acquired by a European aerospace company, according to a law firm that represents the new owner. The law firm Cremades & Calvo-Sotelo, which represents EOS-X Space, announced this week that the company had acquired competitor Space Perspective after a competitive bidding process. EOS-X Space, based in Madrid, plans to operate luxury space tourism flights using high-altitude balloons. Space Perspective appeared to cease operations earlier this year after it was evicted from a Florida airport. The company did not respond to Travel Weekly inquiries earlier this year about its future. The company, which planned to send high-altitude balloons to the edge of space, also faced eviction proceedings from two other landlords. Amid its financial turmoil, Space Perspective ceased communication with clients, leading Signature Travel Network, which had a preferred-supplier agreement with the company, to instruct travel advisors to alert clients who had paid deposits about concerns for the company's future. But now, Space Perspective seems to be back on track to eventual operation with the acquisition, the price of which was not disclosed. Space Perspective will change its name, but that has not been announced, said Juan Miguel Olry de Labry y Lima, the communications manager for Cremades & Calvo-Sotelo. EOS-X Space said Space Perspective will operate autonomously with a U.S.-based headquarters and leadership. The company will retain part of its former team and accelerate operational development, the announcement said. "This is a historic opportunity for two companies that were once rivals to now collaborate in making manned space tourism a reality," said EOS-X Space CEO Kemel Kharbachi in the announcement. Space Perspective will operate a spaceport in Florida at the Kennedy Space Center for near-space flights and an assembly headquarters in California, according to the announcement. It is not clear where Space Perspective will operate within Kennedy Space Center; the company is facing eviction proceedings from landlord Space Florida at the center. "We want to emphasize that this is a completely new operation under different ownership," Olry de Labry y Lima said. "Any unpaid obligations belong to the prior company and are being addressed within the liquidation process. The New Space Perspective has initiated new and independent negotiations with Space Florida for our future operations at the facility." A new company with no contractual obligations The new version of Space Perspective has acquired the technology, assets and intellectual property of the former Space Perspective through an asset purchase agreement, he said. The new company will not assume debts or contractual obligations, including customer contracts or the reservation database. Client deposits for Space Perspective were held in escrow and are under the management of a liquidator or fiduciary as part of bankruptcy proceedings, Olry de Labry y Lima said. Space Perspective planned to charge $125,000 per seat on its capsule, but Olry de Labry y Lima said the company was "reassessing the entire customer journey and value proposition before reopening official sales."

Yahoo
2 hours ago
- Yahoo
💰 América de Cali cash in thanks to Jhon Arias
A Premier League club has signed the 27-year-old Colombian footballer who was playing for Fluminense. One of the most resonant transfers this Thursday in European football has been starred by the Colombian John Arias, who has been signed by Wolverhampton from the Premier League and left money in several FPC teams. Arias, 27, comes to the Wolves from Fluminense of Brazil in exchange for just over 20 million euros, an amount that represents income for Llaneros, America de Cali, Santa Fe and Patriotas Boyacá. 'Mechita', like Llaneros and Santa Fe, will receive 75,000 pounds sterling through FIFA's solidarity mechanism, which ensures that the clubs that contributed to a player's training receive a part of the compensation. In this way, America de Cali has pocketed approximately 300 million Colombian pesos with this transfer of the Colombian attacker who arrives at the elite of English football. Patriotas Boyacá, owner of a larger percentage of his sporting rights, pockets about five million pounds thanks to John Arias making the leap to Europe. This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here.
Yahoo
3 hours ago
- Yahoo
Cocoa Prices Finish Sharply Lower as Chocolate Demand Wanes
September ICE NY cocoa (CCU25) on Thursday closed down -316 (-3.74%), and September ICE London cocoa #7 (CAU25) closed down -122 (-2.23%). Cocoa prices gave up an early advance Thursday and settled sharply lower due to concerns about chocolate demand. On Tuesday, chocolate maker Lindt & Spruengli AG lowered its margin guidance for the year due to a larger-than-expected decline in first-half chocolate sales. More News from Barchart Coffee Prices Underpinned by Frost Concerns in Brazil Cocoa Prices Jump on Fears of Tighter Supplies Prospects of Higher Indian Sugar Exports Weigh on Prices Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Also, chocolate maker Barry Callebaut AG reduced its sales volume guidance earlier this month for a second time in three months, citing persistently high cocoa prices. The company projects a decline in full-year sales volume and reported a -9.5% drop in its sales volume for the March-May period, the largest quarterly decline in a decade. Cocoa prices initially climbed to 2-week highs Thursday on concerns that a slowdown in the pace of Ivory Coast cocoa exports will tighten global supplies. Monday's government data showed that Ivory Coast farmers shipped 1.74 MMT of cocoa to ports this marketing year from October 1 to July 20, up +6.1% from last year but down from the much larger +35% increase seen in December. A significant short position by commodity funds in London cocoa futures raises the potential for short covering. Last Friday, ICE Futures Europe reported that funds boosted their net-short London cocoa positions by 1,010 to 6,361 short positions the week ended July 15, the most in more than two years. Cocoa prices sold off last week, with NY cocoa sinking to an 8-month nearest-futures low last Thursday and London cocoa slumping to a 17-month nearest-futures low. Weakness in global cocoa demand has hammered prices. The European Cocoa Association reported last Thursday that Q2 European cocoa grindings fell by -7.2% y/y to 331,762 MT, a bigger decline than expectations of -5% y/y. Also, the Cocoa Association of Asia reported that Q2 Asian cocoa grindings fell -16.3% y/y to 176,644 MT, the smallest amount for a Q2 in 8 years. North American Q2 cocoa grindings fell -2.8% y/y to 101,865 MT, which was a smaller decline than the declines seen in Asia and Europe. In a bearish development, ICE-monitored cocoa inventories held in US ports reached a 10.5-month high of 2,368,141 bags on Tuesday. Higher cocoa production by Ghana is bearish for cocoa prices. On July 1, the Ghana Cocoa Board projected the 2025/26 Ghana cocoa crop would increase by +8.3% y/y to 650,000 from 600,000 MT in 2024/25. Ghana is the world's second-largest cocoa producer. Cocoa prices have support from quality concerns regarding the Ivory Coast's mid-crop cocoa, which is currently being harvested through September. Cocoa processors are complaining about the quality of the crop and have rejected truckloads of Ivory Coast cocoa beans. Processors reported that about 5% to 6% of the mid-crop cocoa in each truckload is of poor quality, compared with 1% during the main crop. According to Rabobank, the poor quality of the Ivory Coast's mid-crop is partly attributed to late-arriving rain in the region, which limited crop growth. The mid-crop is the smaller of the two annual cocoa harvests, which typically starts in April. The average estimate for this year's Ivory Coast mid-crop is 400,000 MT, down -9% from last year's 440,000 MT. On May 30, the International Cocoa Organization (ICCO) revised its 2023/24 global cocoa deficit to -494,000 MT from a February estimate of -441,000 MT, the largest deficit in over 60 years. ICCO said 2023/24 cocoa production fell by 13.1% y/y to 4.380 MMT. ICCO stated that the 2023/24 global cocoa stocks-to-grindings ratio declined to a 46-year low of 27.0%. Looking ahead to 2024/25, ICCO on February 28 forecasted a global cocoa surplus of 142,000 MT for 2024/25, the first surplus in four years. ICCO also projected that 2024/25 global cocoa production will rise +7.8% y/y to 4.84 MMT. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on